Primary signet-ring cell carcinoma of the urinary bladder successfully managed with cisplatin and gemcitabine: a case report

Journal of Medical Case Reports

Afaf Amarti²  Hind Elfatmi²  Nawal Hammas²  My Hassan Farih¹  Mohammed Jamal El Fassi¹  Omar Riyach¹  Mustapha Ahsaini¹  Jalal Eddine El Ammari¹ 

[1] Department of Urology, University Hospital Center Hassan II, Route Sidi Hrazem, Fez, 30000, Morocco;Department of Pathology, Hospital University Center Hassan II, Route Sidi Hrazem, Fez, 30000, Morocco

关键词: Chemotherapy;    Urinary bladder;    Adenocarcinoma;    Primary signet-ring cell carcinoma;   

Others  :  1181282
DOI  :  10.1186/1752-1947-7-37

 received in 2012-05-29, accepted in 2012-12-06,  发布年份 2013

【 摘 要 】

Introduction

Primary signet-ring cell carcinoma of the urinary bladder is a rare variant of mucus-producing adenocarcinoma constituting approximately 0.5% to 2.0% of all primary carcinomas of the bladder. This tumor initially presents as a high-grade, high-stage lesion and diffusely invades the bladder wall without forming intraluminal growth. The patients have no specific symptoms, which leads to delayed diagnosis and poor prognosis.

Case presentation

We report the case of a 51-year-old Moroccan Berber man consulting for gross hematuria. Ultrasonography and a computed tomography scan found a bladder tumor diffusely invading the bladder wall. A histopathological examination of the tumor chips from a transurethral resection of the bladder revealed signet-ring cell adenocarcinoma. The gastrointestinal tract exploration did not reveal any other tumor localization. A radical cystectomy and adjuvant cisplatin and gemcitabine chemotherapy were therefore performed resulting in 18 months of survival without metastasis and a good quality of life within that time.

Conclusion

The rarity and the successful management with carboplatin and gemcitabine as adjuvant chemotherapy of this entity, which is rarely reported in the literature, are two remarkable characteristics described in this case report.

【 授权许可】

   
2013 El Ammari et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Saphir O: Signet ring cell carcinoma of the bladder. Am J Pathol 1955, 31:223-231.
• [2]Sunghwan J, Soojin J, Kweonsik M, Jae-il C, Sunghyup C, Dongil K: Primary signet ring cell carcinoma of the urinary bladder. Korean J Urol 2009, 50:188-191.
• [3]Torenbeek R, Koot RA, Blonjous CE, De Bruin PC, Newling DW, Meijer CJ: Primary signet-ring cell of the urinary bladder. Histopathology 1996, 28:33-40.
• [4]Yamamoto S, Ito T, Akiyama A, Miki M, Tachibana M, Takase M, Matsumoto T, Mochizuki M: Primary signet-ring cell carcinoma of the urinary bladder including renal failure. Int J Urol 2001, 8:190-193.
• [5]El-Mekresh MM, El-Baz MA, Abol-Enein H, Ghoneim MA: Primary adenocarcinoma of the urinary bladder: a report of 185 cases. British J Urol 1998, 82:206-212.
• [6]Krichen Makni S, Ellouz S, Khabir A, Daoud J, Boudawara T: Primary signet ring cell carcinoma of urinary bladder. A case report. Cancer Radiother 2005, 9:322-324.
• [7]Erdogru T, Kiligaslan I, Esen T: Primary signet ring cell carcinoma of the urinary bladder: review of the literature and report of two cases. Urol Int 1995, 55:34-37.
• [8]Hirano Y, Suzuki K, Fujita K, Furuse H, Fukuta K, Kitagawa M, Aso Y: Primary signet ring cell carcinoma of the urinary bladder successfully treated with intra-arterial chemotherapy alone. Urology 2002, 59:601.